S&P 500 Futures Decline In Premarket Trading; Vaxcyte, PTC Lead
Dow Jones2026/10/05 11:30This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Vaxcyte Inc. (PCVX) was up 54.1% in pre-market trading, and PTC Inc. (PTC) was up 36.2%. Bio-Rad Laboratories Inc. Cl A (BIO), XP Inc. Cl A (XP), and Nu Holdings Ltd. Cl A (NU) were all posting gains of at least 11%. In early trading, Watts Water Technologies Inc. Cl A (WTS) and Westlake Corp. (WLK) had posted declines, falling 13.0% and 11.2%, respectively. Meanwhile S&P 500 futures were down 0.07%, with futures for the Dow Jones Industrial Average falling 0.06%. The Cboe Volatility Index futures were down 1.93%. In commodities news, Brent crude oil futures were up 0.12%, while gold futures were up 0.65%. Bitcoin climbed 0.68% to $86,005. The 10-Year Treasury yield slipped to 5.262%. In the previous regular trading session, the S&P 500 and the Dow were up 0.73% and 0.49%, respectively. In Asia overnight, Japan's NIKKEI 225 Index was up 2.40%. In afternoon trading, stocks in Europe are up, with the STOXX Europe 600 Index rising 0.32% and the FTSE 100 Index climbing 0.29% from the previous close. U.S. stock markets open for trading at 9:30 a.m. ET. Data source: Dow Jones Market Data, FactSet. Data compiled October 05, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires October 05, 2026 07:30 ET (11:30 GMT)
This article was automatically generated by Barrons.com using technology from Automated Insights.
With U.S. stock markets set to open in two hours, Vaxcyte Inc. (PCVX) was up 54.1% in pre-market trading, and PTC Inc. (PTC) was up 36.2%.
Bio-Rad Laboratories Inc. Cl A (BIO), XP Inc. Cl A (XP), and Nu Holdings Ltd. Cl A (NU) were all posting gains of at least 11%. In early trading, Watts Water Technologies Inc. Cl A (WTS) and Westlake Corp. (WLK) had posted declines, falling 13.0% and 11.2%, respectively.
Meanwhile S&P 500 futures were down 0.07%, with futures for the Dow Jones Industrial Average falling 0.06%. The Cboe Volatility Index futures were down 1.93%.
In commodities news, Brent crude oil futures were up 0.12%, while gold futures were up 0.65%. Bitcoin climbed 0.68% to $86,005.
The 10-Year Treasury yield slipped to 5.262%.
In the previous regular trading session, the S&P 500 and the Dow were up 0.73% and 0.49%, respectively. In Asia overnight, Japan's NIKKEI 225 Index was up 2.40%.
In afternoon trading, stocks in Europe are up, with the STOXX Europe 600 Index rising 0.32% and the FTSE 100 Index climbing 0.29% from the previous close.
U.S. stock markets open for trading at 9:30 a.m. ET.
Data source: Dow Jones Market Data, FactSet. Data compiled October 05, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 05, 2026 07:30 ET (11:30 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ido Ben-Natan: Frequent on-chain security incidents, AI agents will increase risks
BTC rebounds and breaks through 83,000 USDT, with a 24-hour decrease of 1%
Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly
The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Crypto prices
More
